Before the opening bell on Wednesday, shares of Altria (MO) rose 0.29% to $44.70 in pre-market trading on Wall Street.
On Tuesday local time, electronic cigarette manufacturer Juul Labs agreed to a $438.5 million cross-state settlement, ending a two-year bipartisan investigation into their marketing and sales practices that negatively impacted youth.
The Juul e-cigarette once held a market share of 70% in the US and was especially popular among American high school students. The trend of underage e-cigarette use caught the attention of the Food and Drug Administration (FDA), prompting Juul to adjust its marketing strategy and discontinue the sale of fruit-flavored e-cigarettes in an effort to appease regulators. However, despite these efforts, Juul was ultimately unable to convince the FDA. In June, it was reported that the FDA planned to reject Juul’s application to continue selling e-cigarettes in the US market.
Tobacco giant Altria Group owns 35% of Juul and has seen a continuous decline in its stock price as a result of Juul's impact.
This article contains excerpts or reprints of third-party information, the copyright of which belongs to the original media and author. If there is any infringement, please contact us to delete it. Any organization or individual wishing to reprint it should contact the author directly and refrain from direct reprinting.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
